161 related articles for article (PubMed ID: 33779091)
1. Comparison of the Prognostic Outcome between High-Grade Ovarian Sertoli-Leydig Cell Tumors (SLCTs) and Low-Grade SLCTs.
Eoh KJ; Park J; Kim HM; Lee M; Kim YT
Yonsei Med J; 2021 Apr; 62(4):366-369. PubMed ID: 33779091
[TBL] [Abstract][Full Text] [Related]
2. Results from a Monocentric Long-Term Analysis of 23 Patients with Ovarian Sertoli-Leydig Cell Tumors.
Gouy S; Arfi A; Maulard A; Pautier P; Bentivegna E; Leary A; Chargari C; Genestie C; Morice P
Oncologist; 2019 May; 24(5):702-709. PubMed ID: 30201740
[TBL] [Abstract][Full Text] [Related]
3. Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients.
Akman L; Ertas IE; Gokcu M; Terek MC; Sanci M; Sanli UA; Zekioglu O; Ozsaran AA
J Cancer Res Ther; 2016; 12(1):290-4. PubMed ID: 27072253
[TBL] [Abstract][Full Text] [Related]
4. Ovarian Sertoli-Leydig cell tumors: an analysis of 13 cases.
Guo Y; Wang J; Li Y; Wang Y
Arch Gynecol Obstet; 2020 Jul; 302(1):203-208. PubMed ID: 32430758
[TBL] [Abstract][Full Text] [Related]
5. DICER1 hotspot mutations in ovarian Sertoli-Leydig cell tumors: a potential association with androgenic effects.
Kato N; Kusumi T; Kamataki A; Tsunoda R; Fukase M; Kurose A
Hum Pathol; 2017 Jan; 59():41-47. PubMed ID: 27664536
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and outcomes analysis of ovarian Sertoli-Leydig cell tumors (SLCTs): analysis of 15 patients.
Wang G; Zhang R; Li C; Chen A
J Ovarian Res; 2021 Nov; 14(1):150. PubMed ID: 34736487
[TBL] [Abstract][Full Text] [Related]
7. Ovarian Sertoli-Leydig Cell Tumors: Epidemiological, Clinical and Prognostic Factors.
Castro BGR; Souza CP; Andrade CEMDC; Vieira MA; Andrade DAP; Reis RD
Rev Bras Ginecol Obstet; 2019 Jul; 41(7):440-448. PubMed ID: 31344718
[TBL] [Abstract][Full Text] [Related]
8. Sertoli-Leydig cell tumor of the ovary: Analysis of a single institution database and review of the literature.
Durmuş Y; Kılıç Ç; Çakır C; Yüksel D; Boran N; Karalök A; Boyraz G; Turan AT
J Obstet Gynaecol Res; 2019 Jul; 45(7):1311-1318. PubMed ID: 31106943
[TBL] [Abstract][Full Text] [Related]
9. Sertoli-Leydig cell tumor: a clinicopathological analysis in a comprehensive, national cohort.
Bekker P; Miland-Samuelsen AR; Smerdel MP; Schnack TH; Lauszus FF; Karstensen SH
Int J Gynecol Cancer; 2023 Dec; 33(12):1921-1927. PubMed ID: 37907261
[TBL] [Abstract][Full Text] [Related]
10. A clinicopathological analysis of 40 cases of ovarian Sertoli-Leydig cell tumors.
Gui T; Cao D; Shen K; Yang J; Zhang Y; Yu Q; Wan X; Xiang Y; Xiao Y; Guo L
Gynecol Oncol; 2012 Nov; 127(2):384-9. PubMed ID: 22850410
[TBL] [Abstract][Full Text] [Related]
11. DICER1 Mutations Are Consistently Present in Moderately and Poorly Differentiated Sertoli-Leydig Cell Tumors.
de Kock L; Terzic T; McCluggage WG; Stewart CJR; Shaw P; Foulkes WD; Clarke BA
Am J Surg Pathol; 2017 Sep; 41(9):1178-1187. PubMed ID: 28654427
[TBL] [Abstract][Full Text] [Related]
12. Well-differentiated Sertoli-Leydig Cell Tumors (SLCTs) Are Not Associated With DICER1 Pathogenic Variants and Represent a Different Tumor Type to Moderately and Poorly Differentiated SLCTs.
McCluggage WG; Rivera B; Chong AS; Clarke BA; Schultz KAP; Dehner LP; Tchrakian N; Apellaniz-Ruiz M; Gilks CB; Kommoss F; Stewart CJR; Foulkes WD
Am J Surg Pathol; 2023 Apr; 47(4):490-496. PubMed ID: 36583307
[TBL] [Abstract][Full Text] [Related]
13. Ovarian Sertoli-Leydig and granulosa cell tumor: comparison of epidemiology and survival outcomes.
Nasioudis D; Mastroyannis SA; F Haggerty A; M Ko E; Latif NA
Arch Gynecol Obstet; 2020 Aug; 302(2):481-486. PubMed ID: 32519016
[TBL] [Abstract][Full Text] [Related]
14. Ovarian Sertoli-Leydig cell tumors. a retrospective MITO study.
Sigismondi C; Gadducci A; Lorusso D; Candiani M; Breda E; Raspagliesi F; Cormio G; Marinaccio M; Mangili G
Gynecol Oncol; 2012 Jun; 125(3):673-6. PubMed ID: 22446621
[TBL] [Abstract][Full Text] [Related]
15. Ovarian Sertoli-Leydig cell tumors: a single institution experience and review of the literature.
Gressel GM; Buza N; Pal L
Eur J Gynaecol Oncol; 2017; 38(2):214-220. PubMed ID: 29953783
[TBL] [Abstract][Full Text] [Related]
16. Ovarian Sertoli-Leydig tumor: A tricky tumor case report.
Khalloufi C; Joudar I; Kanas A; Benhessou M; Ennachit M; El Kerroumi M
Int J Surg Case Rep; 2023 Apr; 105():108043. PubMed ID: 36989630
[TBL] [Abstract][Full Text] [Related]
17. Detection of the DICER1 hotspot mutation alongside immunohistochemical analysis may provide a better diagnostic measure for ovarian Sertoli-Leydig cell tumors.
Zhang X; Shen D; Wang Y
Pathol Res Pract; 2018 Sep; 214(9):1370-1375. PubMed ID: 30072170
[TBL] [Abstract][Full Text] [Related]
18. Clinical Characteristics and Mutation Analyses of Ovarian Sertoli-Leydig Cell Tumors.
Yuan Z; Huo X; Jiang D; Yu M; Cao D; Wu H; Shen K; Yang J; Zhang Y; Zhou H; Wang Y
Oncologist; 2020 Sep; 25(9):e1396-e1405. PubMed ID: 32557933
[TBL] [Abstract][Full Text] [Related]
19. A novel clinicopathological analysis of early stage ovarian Sertoli-Leydig cell tumors at a single institution.
Nam SM; Kim JW; Eoh KJ; Kim HM; Lee JY; Nam EJ; Kim S; Kim SW; Kim YT
Obstet Gynecol Sci; 2017 Jan; 60(1):39-45. PubMed ID: 28217670
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features of ovarian Sertoli-Leydig cell tumors.
Zhang HY; Zhu JE; Huang W; Zhu J
Int J Clin Exp Pathol; 2014; 7(10):6956-64. PubMed ID: 25400781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
